{"uri":"MojoSort-Human-CD45-Nanobeads-Protocols-e2ybgfw","version_id":"0","protocol_name":"MojoSort\u2122 Human CD45 Nanobeads Protocols","protocol_name_html":"MojoSort\u2122 Human CD45 Nanobeads Protocols","is_prepublished":"0","can_edit":"0","parent_id":null,"api_version":"1","is_new_mode":"1","last_modified":"1520661601","type_id":"3","link":"http:\/\/www.biolegend.com\/media_assets\/support_protocol\/MojoSort_Human_CD45_Nanobeads_Protocol_12182015.pdf","fork_id":"","public_fork_note":"","number_of_steps":"2","has_versions":"0","first_published_date":"1464983591","publish_date":"2016-06-03 19:53:11","documents":null,"have_protocol_in_step":"0","is_protocol_in_step":"0","vendor_name":"Contributed by users","vendor_link":"https:\/\/www.protocols.io","vendor_logo":"\/img\/vendors\/1.png","mod_mins":"-45","mod_secs":"1","description":"<p><strong>Note: If the percentage of CD45+ cells in your sample is less than 50%, please follow Protocol A. If it is higher than 50% then please follow protocol B.<\/strong><\/p>\n<p>\u00a0<\/p>\n<p>The cells targeted by the Nanobeads are either selected or depleted by incubating your sample with the directly conjugated magnetic particles. The magnetically labeled fraction is retained by the use of a magnetic separator. After collection of the targeted cells, downstream applications include functional assays, gene expression, phenotypic characterization, etc.<\/p>","is_bookmarked":"0","can_reassign":"1","before_start":null,"has_guidelines":"0","materials":[],"warning":null,"version_class":"2872","public":"1","is_owner":"1","is_original_owner":"1","created_on":"1464977632","protocol_affiliation":"BioLegend","affiliation":"BioLegend","doi":"dx.doi.org\/10.17504\/protocols.io.e2ybgfw","doi_status":"2","changed_fork_steps":null,"profile_url":"Kelsey-w2z29423v2","protocol_img":"https:\/\/s3.amazonaws.com\/pr-journal\/jr3bjf6.jpg","profile_image":"https:\/\/s3.amazonaws.com\/pr-journal\/jikecje.jpg","full_name":"Kelsey Knight","created_by":"Kelsey Knight","private_link":"B9627DDDF1AF5D0957C198B3BE158346","original_img":"1","username":"kelsey-knight","is_retracted":"0","retraction_reason":null,"plos_id":null,"manuscript_citation":null,"journal_name":null,"is_donations_disabled":"0","is_donations_disabled_by_user":"9","item_record_id":229094,"fork_info":[],"compare_forks":[],"protocols":[{"protocol_name":"MojoSort\u2122 Human CD45 Nanobeads Protocol A","protocol_name_html":"MojoSort\u2122 Human CD45 Nanobeads Protocol A","protocol_id":"2873","version_id":"0","last_modified":"1510247633","link":"http:\/\/www.biolegend.com\/media_assets\/support_protocol\/MojoSort_Human_CD45_Nanobeads_Protocol_12182015.pdf","fork_id":null,"number_of_steps":"10","vendor_id":"1","downloads":"0","views":"19","uri":"MojoSort-Human-CD45-Nanobeads-Protocol-A-e2zbgf6","description":"<p><strong>Note: If the percentage of CD45+ cells in your sample is less than 50%, please follow Protocol A. If it is higher <\/strong><\/p>\n<p><strong>than 50% then please follow protocol B.<\/strong><\/p>\n<p>\u00a0<\/p>\n<p>The cells targeted by the Nanobeads are either selected or depleted by incubating your sample with the directly conjugated magnetic particles. The magnetically labeled fraction is retained by the use of a magnetic separator. After collection of the targeted cells, downstream applications include functional assays, gene expression, phenotypic characterization, etc.<\/p>","public":"1","created_on":"1464977763","first_published_date":"2016-06-03 19:51:37","authors":"Kelsey Miller","has_guidelines":"1","has_warning":"0","has_before_start":"0","protocol_affiliation":"BioLegend","doi":"dx.doi.org\/10.17504\/protocols.io.e2zbgf6","doi_status":"2","type_id":"1","created_by":"Kelsey Knight","is_bookmarked":"0","affiliation":"BioLegend","username":"kelsey-knight","first_name":"Kelsey","last_name":"Knight","profile_image":"https:\/\/s3.amazonaws.com\/pr-journal\/jikecje.jpg","protocol_img":"https:\/\/s3.amazonaws.com\/pr-journal\/jr3bjf6.jpg","groups":[{"group_id":"179","group_uri":"biolegend","group_name":"BioLegend","group_logo":"https:\/\/s3.amazonaws.com\/pr-journal\/jr3bjf6.jpg","requested_uid":null,"request_flag":null,"my_request":"1"}],"versions":[{"protocol_id":"2873","protocol_name":"MojoSort\u2122 Human CD45 Nanobeads Protocol A","protocol_name_html":"MojoSort\u2122 Human CD45 Nanobeads Protocol A","protocol_img":"https:\/\/s3.amazonaws.com\/pr-journal\/jr3bjf6.jpg","user_id":"0","uri":"MojoSort-Human-CD45-Nanobeads-Protocol-A-e2zbgf6","version_id":"0","date_created":"2016-06-03 18:16:03","created_on":"1464977763","published_on":"1464983497","full_name":"Kelsey Knight","username":"kelsey-knight","affiliation":"BioLegend","profile_image":"https:\/\/s3.amazonaws.com\/pr-journal\/jikecje.jpg","has_access":"1"}],"forks_count":{"public":"0","private":"0"}},{"protocol_name":"MojoSort\u2122 Human CD45 Nanobeads Protocol B","protocol_name_html":"MojoSort\u2122 Human CD45 Nanobeads Protocol B","protocol_id":"2874","version_id":"0","last_modified":"1514613603","link":"http:\/\/www.biolegend.com\/media_assets\/support_protocol\/MojoSort_Human_CD45_Nanobeads_Protocol_12182015.pdf","fork_id":null,"number_of_steps":"13","vendor_id":"1","downloads":"0","views":"15","uri":"MojoSort-Human-CD45-Nanobeads-Protocol-B-e22bgge","description":"<p><strong>Note: If the percentage of CD45+ cells in your sample is less than 50%, please follow Protocol A. If it is higher than 50% then please follow protocol B.<\/strong><\/p>\n<p>\u00a0<\/p>\n<p>The cells targeted by the Nanobeads are either selected or depleted by incubating your sample with the directly conjugated magnetic particles. The magnetically labeled fraction is retained by the use of a magnetic separator. After collection of the targeted cells, downstream applications include functional assays, gene expression, phenotypic characterization, etc.<br \/><br \/><\/p>","public":"1","created_on":"1464978163","first_published_date":"2016-06-03 19:51:18","authors":"Kelsey Miller","has_guidelines":"1","has_warning":"0","has_before_start":"0","protocol_affiliation":"BioLegend","doi":"dx.doi.org\/10.17504\/protocols.io.e22bgge","doi_status":"2","type_id":"1","created_by":"Kelsey Knight","is_bookmarked":"0","affiliation":"BioLegend","username":"kelsey-knight","first_name":"Kelsey","last_name":"Knight","profile_image":"https:\/\/s3.amazonaws.com\/pr-journal\/jikecje.jpg","protocol_img":"https:\/\/s3.amazonaws.com\/pr-journal\/jr3bjf6.jpg","groups":[{"group_id":"179","group_uri":"biolegend","group_name":"BioLegend","group_logo":"https:\/\/s3.amazonaws.com\/pr-journal\/jr3bjf6.jpg","requested_uid":null,"request_flag":null,"my_request":"1"}],"versions":[{"protocol_id":"2874","protocol_name":"MojoSort\u2122 Human CD45 Nanobeads Protocol B","protocol_name_html":"MojoSort\u2122 Human CD45 Nanobeads Protocol B","protocol_img":"https:\/\/s3.amazonaws.com\/pr-journal\/jr3bjf6.jpg","user_id":"0","uri":"MojoSort-Human-CD45-Nanobeads-Protocol-B-e22bgge","version_id":"0","date_created":"2016-06-03 18:22:43","created_on":"1464978163","published_on":"1464983478","full_name":"Kelsey Knight","username":"kelsey-knight","affiliation":"BioLegend","profile_image":"https:\/\/s3.amazonaws.com\/pr-journal\/jikecje.jpg","has_access":"1"}],"forks_count":{"public":"0","private":"0"}}],"groups":[{"group_id":"179","group_uri":"biolegend","group_name":"BioLegend","group_logo":"https:\/\/s3.amazonaws.com\/pr-journal\/jr3bjf6.jpg","requested_uid":null,"request_flag":null,"my_request":"1"}],"number_of_shared_runs":[],"ownership_history":[],"keywords":"","transfer_to_user":[],"sub_transfer":false,"is_transfer_pending":false,"number_of_bookmarks":"0","collections":[],"tags":[],"archived":0,"sub_authors":[],"sub_protocols_number":0,"can_edit_shared":0,"shared_runs":[],"is_shared_run":0,"is_shared":1,"banner":null,"contact_badges":[{"badge_id":"4","badge_image":"\/img\/badges\/gold.svg","badge_description":"Gold power author!"},{"badge_id":"5","badge_image":"\/img\/badges\/earlyadopter.svg","badge_description":"Early adopter"},{"badge_id":"6","badge_image":"\/img\/badges\/socialbutterfly.svg","badge_description":"Social butterfly"}],"number_of_comments":0,"big_protocol_img":"https:\/\/s3.amazonaws.com\/pr-journal\/jr2bjf6.jpg","big_protocol_img_ofn":"biolegend_square_logo_nocom.jpg","is_locked":0,"is_locked_by":false,"authors":"Kelsey Miller","authors_list":[{"name":"Kelsey Miller","affiliation":"BioLegend","username":null,"profile_image":null}],"user":{"profile_image":"https:\/\/s3.amazonaws.com\/pr-journal\/jikecje.jpg","username":"kelsey-knight","full_name":"Kelsey Knight","created_by":"Kelsey Knight"},"access":{"can_view":"1","can_remove":"0","can_add":"0","can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":"0","can_move":"1","can_transfer":"1","can_download":"1","is_locked":"0"},"is_contact_suspended":0,"guidelines":null,"status_id":"1","is_research":"1","status_info":null,"steps":[{"id":"152954","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"88A4AFE704E74B64B9784EAEC6ABDE40","previous_guid":null,"previous_id":"0","last_modified":"1502718813","components":[{"component_id":"981396","previous_id":0,"original_id":"0","guid":"846C8DC0D00641A59092745412F6D413","previous_guid":null,"component_type_id":"6","data_id":null,"data":null,"order_id":"0","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":null},"is_project":0},{"component_id":"170185","previous_id":"981396","original_id":"0","guid":"D1064AC0F557471790E30CDDCEB8E93E","previous_guid":"846C8DC0D00641A59092745412F6D413","component_type_id":"1","data_id":"0","data":"","order_id":"1","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":""},"is_project":0}]}]}